Oral administration of the ATR inhibitor, AZD6738, decreased growth transiently in ATRX-deficient U251 xenografts, while the combination of temozolomide plus AZD6738 had a more pronounced and persistent inhibitory effect on tumor cell growth (Figure 8). This evidence concerns the gene ATRX and neoplasm.